Cogent Biosciences, Inc. (NASDAQ:COGT) Stock Has Consensus Price Target of $51.56Defense World · Oct 1, 2026
Cogent Biosciences Announces FDA Acceptance of New Drug Application (NDA) for Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)GlobeNewsWire · Sep 15, 2026
Cogent Biosciences: 3 NDAs Create A Time-To-Market MoatSeeking Alpha · Aug 27, 2026
Deutsche Bank AG Takes $10.32 Million Position in Cogent Biosciences, Inc. $COGTDefense World · Aug 24, 2026
Handelsbanken Fonder AB Purchases New Stake in Cogent Biosciences, Inc. $COGTDefense World · Aug 18, 2026
Cogent Biosciences (COGT) May Find a Bottom Soon, Here's Why You Should Buy the Stock NowZacks Investment Research · Aug 13, 2026Cogent Biosciences, Inc. is a biotechnology firm dedicated to creating targeted treatments for illnesses rooted in specific genetic anomalies. The company's primary therapeutic candidate is CGT9486, a selective tyrosine kinase inhibitor engineered to block the KIT D816V mutation, a key driver of systemic mastocytosis, along with other KIT exon 17 mutations observed in individuals suffering from advanced gastrointestinal stromal tumors (GIST). Furthermore, Cogent holds a licensing pact with Plexxikon Inc., granting it rights for the investigation, advancement, and marketing of bezuclastinib.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 10, 2026 | -$0.55 | -$0.52 | Beat |
| May 5, 2026 | -$0.53 | -$0.53 | Beat |
| Feb 17, 2026 | -$0.51 | -$0.55 | Miss |
| Nov 7, 2025 | -$0.54 | -$0.50 | Beat |
| Aug 5, 2025 | -$0.55 | -$0.53 | Beat |
| May 6, 2025 | -$0.56 | -$0.52 | Beat |